Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)

Jul 29, 2025Archiv der Pharmazie

New Developments in 1,2,4-Triazole Cancer Drugs: Improving Structure, How They Work, and Treatment Potential (2022-2025)

AI simplified

Alzheimers & Treatments on OpenScience ↗PubMed ↗DOI ↗

Abstract

Recent studies emphasize the ability of 1,2,4-triazole derivatives to inhibit key cancer-related enzymes.

1,2,4-triazole compounds are noted for their unique properties that contribute to anticancer activity.
Modifications to the 1,2,4-triazole structure have been shown to enhance anticancer efficacy and reduce side effects.
These derivatives may interfere with DNA interactions and influence cell death pathways.
Emerging trends in structure-activity relationships suggest that specific functional group changes can improve drug potency.
Recent evaluations of in vivo studies indicate potential for translating these compounds into clinical applications.

AI simplified

The 1,2,4-triazole scaffold has emerged as a privileged heterocyclic core in the development of anticancer agents due to its unique physicochemical properties, bioavailability, and diverse biological activities. Over the past few years, significant advancements have been made in the design and structural optimization of 1,2,4-triazole-based anticancer compounds, with a strong focus on their structure-activity relationships (SARs). This review provides a comprehensive overview of the latest developments (2022-2025) in 1,2,4-triazole-containing anticancer agents, emphasizing their mechanisms of action, molecular targets, and therapeutic potential. The discussion encompasses the various modifications introduced into the 1,2,4-triazole core, exploring their impact on anticancer efficacy, selectivity, and pharmacokinetic properties. In particular, recent studies have highlighted the ability of these derivatives to inhibit key cancer-related enzymes (such as kinases, carbonic anhydrases, and topoisomerases), interfere with DNA interactions, and modulate apoptotic and autophagic pathways. This review also presents emerging SAR trends, highlighting key functional group modifications that enhance anticancer potency while minimizing off-target effects. Furthermore, recent in vivo studies and clinical evaluations of promising 1,2,4-triazole derivatives are discussed to assess their translational potential. Lastly, we outline future research directions and challenges in the development of next-generation triazole-based anticancer agents, aiming to bridge the gap between rational drug design and clinical application. This comprehensive analysis underscores the critical role of the 1,2,4-triazole pharmacophore in anticancer drug discovery and provides valuable insights for the design of more potent and selective anticancer therapeutics.

Full Text

Full text is available at the source.

View full text ↗

Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the alzheimers & treatments brief